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In addition to causingdistress anddisability to the individual, neuropsychiatric
disorders are also extremely expensive to society and governments. These
disorders are both common and debilitating and impact on cognition, func-
tionality and wellbeing. Cognitive enhancing drugs, such as cholinesterase
inhibitors and methylphenidate, are used to treat cognitive dysfunction in
Alzheimer’s disease and attention deficit hyperactivity disorder, respecti-
vely. Other cognitive enhancers include specific computerized cognitive
training and devices. An example of a novel form of cognitive enhancement
using the technological advancement of a game on an iPad that also acts
to increase motivation is presented. Cognitive enhancing drugs, such as
methylphenidate and modafinil, which were developed as treatments,
are increasingly being used by healthy people. Modafinil not only affects
‘cold’ cognition, but also improves ‘hot’ cognition, such as emotion recogni-
tion and task-related motivation. The lifestyle use of ‘smart drugs’ raises
both safety concerns as well as ethical issues, including coercion and increas-
ing disparity in society. As a society, we need to consider which forms of
cognitive enhancement (e.g. pharmacological, exercise, lifelong learning) are
acceptable and forwhich groups (e.g.military, doctors) underwhat conditions
(e.g. war, shift work) and by what methods we would wish to improve
and flourish.1. Cognitive enhancement in neuropsychiatric disorders
In addition to the increasing prescription use of cognitive enhancers, there is
also a growing lifestyle use by healthy people [1]. The evidence for this trend
comes mostly from increasing sales numbers, in addition to purchases via the
internet and sporadic seizures such as reported in a recent newspaper article
about a £200 000 smart drugs seizure [2]. However, solid longitudinal data
on cognitive enhancing drug use by healthy people using rigorous survey
methodology are needed. There is also a lack of data on the dangers of these
drugs. For example, in the case of the racetam class, piracetam is relatively
well studied. However, the newer racetams being sold via the internet are far
more potent and indeed, some drugs being sold have no published clinical
trials on their safety and efficacy. For these and other neuroethical reasons,
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of Bioethical Issues has reported on cognitive enhancing
drugs as one of the top four priorities in their recent Gray
Matters report [3].
To get a better understanding of potential effects, benefits
and also potential dangers of so-called smart drugs, we first
need to define this group of drugs. From a scientific point
of view, the definition of ‘enhancing’ is difficult: does it
refer to an improvement of a function relative to its previous
level or beyond a particular point [4]? This might seem rela-
tively easy to define in patients with clear cognitive deficits
such as in chronic schizophrenia or stroke, but might prove
more difficult in people without a medical diagnosis but sub-
jective deficits or in healthy people with the wish to improve
their cognitive performance. For example, a healthy person
who is sleep-deprived or jet lagged may want to counteract
that state with cognitive enhancing drugs. Would that be con-
sidered restoration or enhancement? Similarly, an elderly
person who is still working may wish to perform as they
did when they were in their twenties. Again, if they use
cognitive enhancing drugs to obtain their previous optimal
state, would that be considered restoration or enhancement?
From a pharmacological perspective, drugs with a supposed
cognitive enhancing effect can be found in a variety of classes
with a variety of pharmacological targets ranging from acetyl-
choline to serotonin, glutamate, noradrenaline and dopamine,
plus drugs where the mechanism by which they exert their
cognitive enhancing effects is still not fully understood. The
aim of this review is to summarize studies on cognitive
enhancers in patients, including a new study of our group
on a non-pharmacological method of enhancing motivation
and cognition. The review also presents research studies on
healthy volunteers that use drugs as tools to understand the
neuromodulation by neurotransmitters of cognitive processes,
including attention, memory, planning and problem solving.
In addition, the article discusses the increasing use of ‘smart
drugs’ by healthy people as well as the use of neuromodulat-
ing devices in both disorders and health. Finally, we consider
the implications for society and future research directions.
Neuropsychiatric disorders are disorders of cognition.
Cognitive manifestations of neuropsychiatric disorders
include disturbances in the regulation of attention (atten-
tional biases), learning (aberrant learning), and in top–
down regulation by the prefrontal cortex [5]. Furthermore,
impairments of memory and executive function have been
found in many neuropsychiatric disorders [6–12]. Many neu-
ropsychiatric disorders have a neurodevelopmental origin
and an onset or prodromal stage in childhood [13], and
mental disorders affect young people disproportionally,
with 75% of mental illnesses beginning before the age of 24
years. This is the period during which the brain is under-
going major developmental processes, particularly in the
prefrontal cortex [14], which is why it is not that surprising
that environmental influences, such as stress or substance
abuse, may have especially profound effects on prefrontal
functions [5].
Neuropsychiatric disorders affect the functionality and
wellbeing of individuals and pose an economic burden for
society [15]. These disorders are not only costly with respect
to treatment and other services related to disorders, including
special accommodation, social services and informal care, but
even more so when considering the indirect costs, such as lost
income and productivity owing to not finishing school orreaching only low grades, inability to train for a job, lower
academic achievement, absence from work or early retire-
ment [16]. Currently, treatment for mental disorders, both
psychologically and pharmacologically, targets the obvious
symptoms of the disorders, but rarely the cognitive impair-
ments (except for some treatments for Alzheimer’s disease
and attention deficit hyperactivity disorder (ADHD)). These
cognitive symptoms often persist even after remission of
the more acute symptoms of, for example depression or psy-
chosis [17–20], and they have a great impact on the indirect
costs and loss of productivity, quality of life and wellbeing
[21–24]. Therefore, ‘smart drugs’ or cognitive enhancing
drugs are needed to improve cognitive problems in patients
with neuropsychiatric disorders. Improving functionality of
patients suffering from neuropsychiatric disorders will lead
to a reduction of the costs of these disorders for society and
governments in the range of about £90 billion in the UK [25].
A wide variety of interventions that can enhance cogni-
tive performance in mental disorders have been identified
[26]. Some of them are behavioural interventions, such as
exercise, meditation, sleep hygiene or cognitive stimulation
(e.g. cognitive training, CT). Others involve the application
of exogenous agents such as cognitive enhancing drugs or
nutritional supplements with supposedly positive effects on
cognitive performance and mood [27]. A last group of inter-
ventions targets the brain physically by applying
electromagnetic fields to the surface of the skull, e.g. transcra-
nial magnetic stimulation (TMS) or transcranial direct current
stimulation (tDCS). All of these interventions aim to improve
neural circuits in a neuroplastic way and to improve cognitive
functions (including socio-affective functions).(a) Alzheimer’s disease
Alzheimer’s disease, a neurodegenerative disorder character-
ized by a progressive decline in cognitive and everyday
functioning, was one of the first disorders where acetylcholin-
esterase inhibitors were developed and are now approved
and widely used specifically to improve the impaired cogni-
tive function or to reduce the cognitive decline (e.g. [28]). In
Alzheimer’s disease and other dementias the most obvious
symptoms from the beginning are cognitive deficits, one of
the earliest impairments being in episodic memory [29,30].
The current guidelines on pharmacological treatment in
Alzheimer’s dementia consistently recommend early assess-
ment and treatment with cholinesterase inhibiting drugs
such as donepezil, galantamine and rivastigmine beginning
early and continuing as long as tolerated [31–36]. The
NMDA receptor antagonist memantine is also generally
used in later stages of Alzheimer’s disease. Evidence suggests
that these drugs can also be effective even in severe disease
states [31]. There are currently 820 000 people with dementia
in the UK, with one new case every 14 minutes in England
and Wales, and the cost of dementia to the UK economy is
£23 billion per year, which is more than cancer, heart disease
and stroke [32]. The number of people placed in institutions is
expected to rise from 224 000 in 1998 to 365 000 in 2031. How-
ever, early assessment and early effective treatment with
drugs aimed at improving cognitive function have been
shown to reduce overall direct costs by more than £3600
per patient, with another £4150 in indirect cost savings [33],
parallel to an improvement of quality of life for the patient
and the carers.
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Parkinson’s disease (PD) is a chronic progressive neurodegen-
erative disorder typically characterized by motor deficits, but a
majority of patients also suffer from non-motor symptoms that
impact on their quality of life [34]. Non-motor symptoms in
PD include psychiatric symptoms such as mood and affect
symptoms and psychosis, cognitive dysfunction, fatigue and
dementia, and autonomic dysfunction. More than 125 000
people are affected by PD in the UK [35], causing total costs
of about £1.9 billion per year [16]. In parallel to the gradual
loss of function, the need for care increases, placing a high
burden on families and society as a whole. With the increasing
age of the population, the number of persons affected by PD is
expected to rise. The non-motor symptoms contribute con-
siderably to the burden for carers and the reduced quality of
life in PD patients, as well as nursing home placement [36].
Cognitive enhancers have been investigated in order to treat
cognitive dysfunction and fatigue, as well as other dementia
symptoms [37]. Studies have tried to improve fatigue using
methylphenidate [38] and modafinil [39,40], both with only
weak effects. Impulsivity can on the one hand be a symptom
of PD itself, and on the other hand be evoked by treatment
with dopamine agonists in vulnerable patients (review: [41]).
One study using amantadine, an NMDA receptor antagonist
with additional effects on dopamine, norepinephrine and
acetylcholine, found weak effects on clinical measures of gam-
bling in PD [42]. Another study in our laboratory used a single
dose of the noradrenergic reuptake inhibitor atomoxetine [43],
which also has antagonistic effects on the NMDA receptor
[44]. In a double blind placebo-controlled crossover design,
PD patients showed a trend to an improved reaction time
and accuracy on the stop signal reaction test (SSRT), reduced
risk-taking behaviour and increased deliberation time in the
Cambridge Gamble Task [45]. There was also a positive corre-
lation between atomoxetine plasma concentration and
planning performance on the One Touch Stockings of Cam-
bridge task (www.camcog.com). On the neural level, this
effect was associated with an increased activation in inhi-
bition-related brain areas, including the right inferior frontal
gyrus, and fronto-striatal connectivity [46]. These promising
proof-of-concept studies support further testing of atomoxe-
tine treatment in impulsive–compulsive PD in clinical
studies with longer-term treatment. Regarding dementia and
other specific cognitive symptoms, anticholinergic drugs,
such as donepezil and rivastigmine, are considered as effica-
cious but have rather weak effects, whereas the NMDA
receptor antagonist memantine shows no clear positive effect
(review [37]). One study showed improved global cognition
with atomoxetine in PD [47], parallel to another study that
showed improved executive functioning on two clinical
scales of executive function [48].
(c) Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder is a highly heritable dis-
order (in children about 75% heritable; meta-analysis [49],
review [50]) with a 12-month prevalence of 5–6% in children
[51] and about 4% in adults [52]. If ADHD is not treated effec-
tively, the prognosis is complicated by psychiatric comorbidities
such as anxiety, mood and substance-use disorders and impair-
ments in basic, social and productive role functioning [52].
Longitudinal studies indicate that ADHD is associated with
poorer long-term outcomes, including increased educationaldropout, job dismissal, criminal activities, substance abuse,
other mental illnesses and increased accident rates [53], which
can be reduced by treatment [54], but only partially when look-
ing at academic or occupational outcome [53,55]. While
methylphenidate (Ritalinw) is an effective treatment for about
60–70% of people with ADHD, some people do not respond
to treatment or cannot take the treatment owing to side effects
[56]. In addition, methylphenidate is a stimulant drug and
therefore has some abuse potential [57]. For these reasons, it
is important that novel, effective and safe treatments for
ADHD are developed. The annual excess cost of ADHD in
the USA in 2000 was estimated to be $31.6 billion [58].
Working memory is one of the cognitive domains
impaired in ADHD in childhood [59,60] and adulthood [61].
Methylphenidate, acting primarily by increasing the synaptic
concentration of dopamine and noradrenaline by blocking
their re-uptake, improves spatial working memory perform-
ance in adult patients with ADHD [62] and in healthy
volunteers [63]. On the neural level, the main effect of methyl-
phenidate is an increase in efficiency of the networks involved
in working memory [64]. The main locus of action in both
patients with ADHD and in healthy volunteers is the striatum
[65]. However, this mechanism seems not to be different
between patients with ADHD and healthy volunteers, who
do not differ with respect to their dopamine D2/3 receptor
capacity at baseline [65]. Furthermore, methylphenidate
improved and normalized the stop signal reaction time in
boys with ADHD [66]. A recent meta-analysis of methylpheni-
date effects in children and adolescents confirmed this positive
effect on response inhibition, as well as on the increased reac-
tion time variability [67]. In parallel, modafinil improved
response inhibition in ADHD [68]. Atomoxetine also
improved response inhibition in adult patients with ADHD
[69], but did not affect sustained attention and spatial working
memory.(d) Schizophrenia
Schizophrenia is a paradigmatic disorder where cognitive def-
icits on the one hand are a core domain [8,70,71] and on the
other hand are known to be an important determinant of
functional outcome through their impact on the level of
self-care and utilization of hospital services [72–76]. Overall,
summing-up direct and indirect costs, schizophrenia is esti-
mated to cost £ 13.1 billion per year in total in the UK
[16,77]. However, even small improvements in cognitive func-
tions could help patients make the transition to independent
living and working [26,74] and could therefore reduce direct
and indirect costs markedly, besides improving the wellbeing
and health of patients. Cognitive deficits are typically found
in memory, cognitive flexibility and visuospatial learning
[78]. In patients with a first psychotic episode, modafinil
improved working memory [71] and also emotion recognition
[79]. In patients with manifest schizophrenia, modafinil
improved cognitive flexibility, measured with the intra-extra-
dimensional attentional set shifting task [80]. Other studies
showed improved motor activity [81] and improved clinical
condition and self-reported quality of life, as well as improved
cognitive performance on a subtest of the Wechsler adult
intelligence scale [82]. On the neurobiological level, modafinil
increased dorsolateral prefrontal cortex (DLPFC) activity, par-
ticularly in schizophrenia patients with cognitive dysfunction
[83]. Acetylcholinesterase inhibitors, such as donepezil and
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schizophrenia (reviewed in [84]). Galantamine acts as cholin-
esterase inhibitor, but also on nicotinic acetylcholine receptors
parallel to nicotinic agonists such as xanomeline and DMXB-
A and nicotine. Galantamine improved certain cognitive
functions in schizophrenia, but further research studies are
required [84,85].
There is a great need to develop novel, more effective
cognitive-enhancing drugs to improve cognition, functionality
and wellbeing in patients. However, regrettably, many
pharmaceutical companies have left the field of drug develop-
ment in neuropsychiatric disorders, such as ADHD and
schizophrenia, although some remain in pursuing neuroprotec-
tive treatments for neurodegenerative conditions such as
Alzheimer’s disease [86]. For this and other reasons, including
the explosion of technological advances underused in mental
healthcare, there is an unmet need to develop cognitive
enhancement techniques, such as CT, which can be used on
a much larger scale [5,87]. As an example of these possibilities
that represent the futurescoping of cognitive enhancement, we
present data on CT of memory using an iPad game in patients
with schizophrenia. As apathy, anhedonia and negative symp-
toms are typical of chronic neuropsychiatric disorders,
the game training has the added advantage of increasing
motivation. This latter feature of CT games is particularly
important as patients actively enjoy participating, in contrast
to the traditional CT, which may seem tedious or boring.
(e) A study on computer-game-based CT in
schizophrenia
Cognitive remediation therapies for schizophrenia result in
improvements in cognition, symptoms and psychosocial
functioning, particularly when combined with neuropsychia-
tric rehabilitation (meta-analyses: e.g. adjunctive social skills
training, vocational training; [88,89]). Of particular interest,
recent computer-assisted cognitive rehabilitation and training
studies have successfully shown improvements, not only in
cognitive functioning, but also in negative symptoms [90], rea-
lity monitoring [91], social cognition [92] and employment
[93,94] and functional [95] outcomes in schizophrenia. We
therefore conducted a study to test the promise of computer-
based rehabilitation programmes for schizophrenia and
further suggest their potential for helping patients achieve
better functional outcomes (e.g. work, independent living),
one critical component of rehabilitation. A recent systematic
review of rehabilitation studies for schizophrenia concluded
that a range of cognitive domains could be improved using
computerized practice, suggesting that episodic memory diffi-
culties may be one cognitive dysfunction amenable to
computer-based CT [96]. Therefore, we focused on episodic
memory for training, because we had previously demon-
strated that it was related to functional outcome in patients
with first episode psychosis, and because we had a strong
understanding of the underlying neurocircuitry involved
[29,97]. However, CT packages typically require supervision
on standard psychological paradigms. Sessions are often
long and repetitive; dropout rates can be high and cost
efficiency is limited by the requirement for constant supervi-
sion. For example, Wykes et al. [88] note that the dropout
rate for 12 of the studies included in their meta-analysis of cog-
nitive remediation for schizophrenia was higher than 15%.
Recent neuroscience and mental health policy reports suggestthat the use of neurotechnologies, such as video-game train-
ing, is a potential technique for enhancing cognitive
performance in schizophrenia [86,87,98–100]. Computer-
based CT taking the form of a neurotechnology (i.e. ‘brain
training’ software), for example, has already been shown to
improve verbal learning/memory and cognitive control in
individuals with schizophrenia. Importantly, improved cogni-
tion was associated with better functioning 6 months after
completing the training intervention [101]. Use of a computer
game as a means of cognitive remediation has also been
shown to improve negative symptoms and executive function
in a small number of individuals with first episode psychosis
[102]. Furthermore, video game playing has been associated
with structural neural changes, including a significant grey
matter increase in the hippocampal formation in healthy indi-
viduals [103]. Computer games that are custom-made to be
enjoyable, attention-grabbing and easily accessible may thus
comprise an appealing treatment option for patients and a
cost effective option for health services.
In this study, we developed a novel memory game for deli-
vering CT of episodic memory using a hand-held portable iPad.
This game embedded a paired associative learning (PAL) task
into a narrative, which allowed for the selection of characters,
rewarded progress, provided feedback and used visually
appealing displays and stimulatingmusic to keepusers engaged
and motivated. The Cambridge neuropsychological test auto-
mated battery (CANTAB) PAL task is a sensitive measure of
episodic memory that has been shown to engage the hippocam-
pal formation [29].We aimed to test the effectiveness of 8 h ofCT
(i.e. gameplay) on memory and daily functioning in individuals
with schizophrenia. We also measured participants’ level of
enjoyment and motivation to continue gameplay to determine
whether a wider application to other patient groups would be
feasible for future larger studies.(i) Methods
Twenty-two participants were recruited from public health ser-
vices within the Cambridgeshire and Peterborough Foundation
Trust (CPFT), including the Cambridge Assessment and Man-
agement of Early Outcomes service (CAMEO; www.cameo.
nhs.uk) and the Rehabilitation and Recovery Service, as well
as analogous services in other parts of the UK (see table 1 for
demographic information). Inclusion criteria were patients
with a clinical diagnosis of schizophrenia as determined by
the SCID-P16 [104] or DSM-5 [105] or a related condition (e.g.
schizoaffective disorder, schizophreniform disorder). All
patients were clinically stable and treated with anti-psychotic
medication during the course of the study, except for five
patients (one pregnant; four recently discharged from specialist
clinical services). Participants were excluded from the study if
they had a current or past neurological condition or disorder,
including epilepsy or head trauma with loss of consciousness.
Only adults (age. 16) were recruited. Participants were
excluded if they did not have normal or corrected-to-normal
vision (6/9 or better). This study received full ethical approval
by the Cambridge Central Research Ethics Committee (12/
EE/0018). All participants gave written consent prior to enrol-
ling. To reduce placebo effects, participants were not informed
at the time of testing that the study concerned CT of episodic
memory, but rather were told that the aim was to investigate
the effect of iPad use on psychological processes. Participants
were randomly assigned to either the CT or treatment as
Table 1. Demographic data (baseline). Independent samples t-test, x2-square test. For CT group and TAU group, data shown are means, with standard
deviations in parentheses.
measure CT group TAU group statistics
N 10 12
gender 5 M: 5 F 6 M: 6 F
age 28.70 (6.89) 28.3 (9.15) t(20) ¼ 0.10, p ¼ 0.92
years of education 13.90 (3.93) 15.42 (3.55) t(20) ¼ 20.95, p ¼ 0.35
NART 104.10 (16.57) 102.25 (10.41) t(20) ¼ 0.32, p ¼ 0.75
BPRS 54.90 (8.88) 52.75 (15.45) t(20) ¼ 0.41, p ¼ 0.69
NEGATIVE symptoms 2.53 (1.04) 2.69 (1.32) t(20) ¼ 20.04, p ¼ 0.97
chlorpromazine equivalents (mg) 385.00 364.00 t(15) ¼ 0.16, p ¼ 0.87
unmedicated 1 4 x2-square ¼ 1.69, p ¼ 0.19
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National Adult Reading Test (NART [106]) and the Brief Psy-
chiatric Ratings Scale (BPRS, [107]) as measures of intelligence
and psychiatric symptoms, respectively. Participants in the CT
group played the memory game for a total of 8 h over
a 4-week period; participants in the TAU group continued
their TAU. All participants completed the CANTAB PAL and
the Global Assessment of Functioning (GAF, [108]) at both
baseline and outcome time points. The outcome testing session
took place exactly 4 weeks after the baseline testing session.
The CANTAB PAL is an episodic memory task comprised of
one-pattern, two-patterns, three-patterns, six-patterns and
eight-patterns stages. The GAF was used to numerically rate
participants’ social, occupational and psychological function.
The BPRS results in a sum score, andwe additionally calculated
a negative symptom score by averaging the BPRS subscales
Emotional Withdrawal, Motor Retardation and Blunted Affect
[109]. Statistical analyses were done using SPSS 20. We used
t-tests, Mann–Whitney tests, ANCOVAs and bivariate correla-
tions as appropriate, depending on the normality of the
distribution of the data. As the PAL total errors and total trials
werenot normallydistributed, thevalueswere square root trans-
formed for statistical analyses. However, for better comparison
with other studies, table 2 reports the absolute scores.(ii) Memory game development
To ensure that our training programme took the form of a
memory game rather than a standard psychological test, we
employed a professional game designer who was briefed to
develop an entertaining game that incorporated a learning
and episodic memory task into a narrative. Once a prototype
had been developed—using six focus groups, each with two
individuals with a diagnosis of schizophrenia—the game was
further developed until focus group participants agreed that
the game was fun, attention-grabbing, motivating and easy to
understand. The game required the patient to remember cor-
rectly the location of patterns in space. The game started in an
easy stage at the beginning but increased in difficulty as the
participant succeeded, using a ‘three up one down’ adaptive
staircase, with the highest level requiring participants to
memorize the locations of 20 runes. The memory game
employed a number of strategies to maintain a high level of
motivation to continue gameplay: the episodic memory
task was woven into a narrative with individualized aspects(choice and name of the character), appealing design and sti-
mulating music; the game rewarded progress with additional
in-game activities to provide the user a sense of progression
independent of the CT process while minimizing failure.
After each hour of gameplay (hours 1–8), participants in the
CT group completed a visual analogue scale to rate their
enjoyment and motivation to continue playing the game
(scores ranged from 0 to 100, with higher scores indicating
enhanced enjoyment/willingness to continue).(iii) Results
Twenty-two participants (11 male; 11 female) with a diagno-
sis of schizophrenia were randomly assigned to either the CT
(n ¼ 10) or TAU (n ¼ 12) group and completed all tasks and
questionnaires required of their condition. These groups
showed no significant differences in intelligence, age, years
of education and psychiatric symptoms (including negative
symptoms) at baseline assessment (table 1). When analysing
performance on the CANTAB PAL, we focused on the eight-
pattern stage, the highest level of task difficulty (table 2). At
outcome assessment, the CT group made significantly fewer
errors and needed significantly fewer attempts to remember
the location of different patterns (trial score) relative to the
TAU group. The CT group also correctly located more patterns
at the first attempt of the eight-pattern stage at outcome
assessment. Furthermore, mean GAF scores improved signifi-
cantly in the CT group from baseline to outcome assessment
(table 2). When conducting ANCOVAs including covariates
such as baseline measures, the pattern of results did not sub-
stantially change. During training, participants’ levels of
enjoyment and motivation to continue playing were monitored
using visual analogue scales on an hourly basis. Participants in
the CT group indicated that they enjoyed the game and were
motivated to continue playing across the 8 h of CT (all ratings
were higher than 65% across all hours of play; figure 1d).
One-sample t-tests comparing participants’ average enjoyment
and motivation to continue playing across the 8 h demon-
strated significantly higher means than 50% (i.e. the level of
indifference on the visual analogue scales) for enjoyment
(t(9)¼ 15.12, p, 0.001, mean enjoyment level¼ 71.59, s.d.¼
4.03) and motivation (t(9)¼ 15.38, p, 0.001, mean motivation
level¼ 72.32, s.d.¼ 4.10). Correlational analyses further
demonstrated that iPad peak performance (i.e. the highest
level attained out of a total of 20 levels on our memory
Table 2. Performance on the CANTAB PAL and GAF scores at baseline and outcome assessments. The baseline and outcome data shown are means, with
standard deviations in parentheses. PAL, paired associates learning task.
PAL measure baseline statistics outcome statistics
errors CT: 9.33 (9.47)
TAU: 13.55 (13.44)
t(18) ¼ 21.02,
p ¼ 0.32
CT: 3.00 (4.61)
TAU: 10.27 (10.56)
t(18) ¼ 22.38,
p ¼ 0.03a
trials CT: 2.90 (2.02)
TAU: 5.00 (2.86)
t(18.04) ¼ 22.04,
p ¼ 0.06
CT: 1.90 (1.19)
TAU: 4.5 (3.05)
t(19.98) ¼ 22.83,
p ¼ 0.01a
ﬁrst trial memory score CT: 29.50 (18.56)
TAU: 17.81 (4.53)
t(9.87) ¼ 1.93,
p ¼ 0.08
CT: 45.00 (23.91)
TAU: 22.72 (9.82)
t(11.72) ¼ 2.74,
p ¼ 0.02
GAF CT: 64.10 (24.88)
TAU: 65.42 (26.80)
t(20) ¼ 20.12,
p ¼ 0.91
CT: 72.00 (24.95)b
TAU: 64.91 (22.15)
t(20) ¼ 22.19,
p ¼ 0.04c
aIndependent samples t-tests were performed on square root transformed data owing to a non-normal distribution.
bA paired-samples t-test indicated that mean GAF scores signiﬁcantly improved within the CT group, t(9) ¼ 23.30, p ¼ 0.009.
cIndependent samples t-test of the changes in GAF scores in the CT group.
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level of motivation (p ¼ 0.03, Spearman’s R ¼ 0.68), confirm-
ing that high levels of performance were associated with
task-related (i.e. game play) motivation.
As predicted, we found that individuals who completed 8 h
of gameplay showed improved performance on the PAL task in
terms of reduced errors, improved trial score and the correct
number of patterns located (table 2 and figure 1a–c). Although
further studies with larger sample sizes are required to confirm
the clinical generalizability of our current findings (including
the potential for transfer effects on other cognitive domains),
our data suggest that those who completed training were able
to achieve better performance as the difficulty of the task
increased. It is possible that use of a computer game (rather
than standard cognitive testing using a computer) helped main-
tain participants’ motivation to perform well at a higher level of
task difficulty. Non-significant group differences in the BPRS at
baseline confirm that the effects of CT could not be attributed to
baseline differences in psychiatric symptoms. Given the repeti-
tive nature of most CT programmes, it is plausible that
participants’ level of enjoyment might decrease over time. In
contrast, enjoyment levels associated with playing computer
games might increase as players reach more difficult levels
and can ‘unlock’ more of the game’s potential. We observed
that participants’ enjoyment and motivation to continue playing
were maintained throughout all hours of training, suggesting
that our memory game had the same motivational engagement
associated with typical computer games.
Enhanced performance at a higher level of the PAL task
may represent strengthened competency in the specific net-
work underlying episodic memory, yet importantly, we also
found improved functional outcome in the CT group as
measured by the GAF at outcome assessment. This suggests
that the effectiveness of our memory game might not be lim-
ited to improved episodic memory, but it also has the
potential to improve functioning in activities of daily living.
This functional improvement could be driven by several poss-
ible mechanisms. For example, improvements in memory may
have had a direct impact on global functions. An alternative
explanation is that CT may have had an indirect impact on
functionality by improving low self-esteem. Or indeed, both
of these explanations may have played a role in terms of the
impact of training on functional outcome. The mainlimitations of this study are the lack of an active comparison
group, such as iPad use without a training game, and the rela-
tively small sample size. Nevertheless, the patients were
relatively severely ill and well matched such that they are
still representative of patients suffering from schizophrenia.
Further research with larger sample sizes and active control
conditions is required to elucidate the psychological mechan-
isms underpinning the global functioning improvements
observed here. These results add to a growing body of literature
that attests to the efficacy of CT programmes in schizophrenia.
Despite support for its therapeutic benefits, CT remains an
underused therapeutic option. Potential explanatory factors for
this include the longperiods of supervised training that are typi-
cally required, the need to attend a clinic or hospital setting and
the lack of enjoyable, attention-grabbing tasks. This study over-
came these limitations through development of a portable
hand-held memory game that would be fun for patients to
play and concurrently have the potential to provide thera-
peutic benefits. Here, the iPad game was the result of a 9-
month collaboration between psychologists, neuroscientists,
a professional game-developer and service users. To the best
of our knowledge, this is the first study to have developed a
neurotechnology using feedback directly from individuals
with schizophrenia to ensure that the narrative was under-
standable and that playing the game was highly enjoyable.
We also used a neurobiological approach to CT based on pre-
vious neuropsychological and neuroimaging published
findings. These data suggest that use of neurotechnologies
may serve to complement current psychological therapies
and/or psychopharmacological treatments for schizophrenia.
Neurotechnologiesmay also have potential as treatment appli-
cations in other groups, such as healthy elderly individuals or
patients groups with memory-related difficulties (e.g. mild
cognitive impairment; traumatic brain injury). Using modern
technology inmental healthmay be onemethod for improving
patients’ active engagement in treatments [5].
( f ) Summary: cognitive enhancers in neuropsychiatric
disorders
In summary, there is a demand for improving and developing
treatments for cognitive deficits in neuropsychiatric disorders.
In some disorders, such as ADHD and Alzheimer’s disease,
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Figure 1. Memory game training in schizophrenia: the cognitive training (CT) group made fewer errors (a), needed fewer trials to target (b) and correctly located
more patterns at the first attempt (c) of the eight-pattern stage on the PAL task than the treatment as usual (TAU) group. The CT group indicated that they enjoyed
playing the game and were motivated to continue across all hours of cognitive training (all ratings higher than 65%) (d ).
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treating them, resulting in a sufficient basis for clinical decisions.
However, in many other neuropsychiatric disorders, cognitive
symptoms have not been fully defined, nor have they been
regarded as targets for treatment. Therefore, studies on the func-
tion and dysfunction of cognitive domains in neuropsychiatric
disorders and their manipulation by pharmacological agentsin healthy states and in neuropsychiatric disorders as well as
the development of novel cognition-modifyingdrugs are necess-
ary. In addition, it is important to harness the potential of novel
devices and technologies for improving functioning, quality of
life and wellbeing in healthcare in general, and in particular in
neuropsychiatric disorders. Although experts realize the poten-
tial of these inventions and technologies in the treatment of
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health [5].
Furthermore, studies on the combination of different
treatment strategies, including for example, combinations
of cognitive enhancing drugs and/or CT with anti-psycho-
tics, antidepressants, psychotherapy and the optimal time
point in the course of a disorder (acute episode versus
early remission versus relapse prevention), are urgently
needed.
From an ethical perspective, there can be few doubts
about research, development and use of cognition-enhancing
drugs in neuropsychiatric disorders, as in these disorders the
suffering of the affected individuals, their families and the
burden for society are clearly significant and any successful
treatment will have widely accepted benefits. In a clinical set-
ting, the neuropsychiatric patients will be monitored by a
healthcare professional in regard to drug–drug interactions,
counterindications and side effects. Therefore, the evidence
base on safety will increase with increasing use, such that
in future, benefits and risk can be better evaluated.
In §2, we discuss the increasing lifestyle use of cognitive
enhancers by healthy people.2. Cognitive enhancers in healthy people
The drugs used in patients are all prescription drugs. From a
legal perspective, amphetamine and methylphenidate are
classified as schedule II drugs, and therefore not legally
obtainable without medical prescription. The reason for
these limitations is the abuse potential of these drugs.
Owing to the lower abuse risk, modafinil is a prescription-
only drug, but not scheduled in countries such as UK,
USA, Canada, Germany and Australia. However, owing to
their performance-modulating effects, all these drugs are
banned as doping substances in sports competitions.
(a) Effects of amphetamine, methylphenidate and
modafinil in healthy people
The Care Quality Commission reported that over a six year
period from 2007 to 2013, there had been a 56% rise in pre-
scriptions for methylphenidate in the UK. They attributed
this increase to its use in the management of childhood and
adult ADHD, but importantly, also, to its potential for diver-
sion and misuse [1]. Recent reviews summarizing the effects
of amphetamine and methylphenidate on cognitive perform-
ance in healthy participants showed a couple of consistent
effects in the following domains [110,111].
Learning is positively affected by both drugs, but primarily
when testingdelayedrecall and recognition, pointing toan effect
onmemory consolidation [110].When testing the effects on pre-
frontal functions such as attention, workingmemory, inhibition
andplanning, thebiggest effectswere found inparticipantswith
lower than optimal performance [65]. In studies of inhibitory
control in healthy volunteers, positive effects were found with
modafinil [112]. In working memory tasks, the findings were
moremixed,with some studieswithmodafinil finding improve-
ments in working memory with reduced errors or reduced
reaction time [113] and others reporting no effect. The reason
for these mixed findings might also be influenced by baseline
effects (reduced effect in high-performing participants). For
example, Muller et al. [113] used a difficult version of theCANTAB spatial working memory test, thus avoiding ceiling
effects, and found that modafinil improved the performance of
healthy volunteers. Inhibitory cognitive control processes are
significantly improvedbyamphetamine andmethylphenidate.
Other executive functions such as planning (Tower of London,
strategic choice task, sequence forming) and fluency have also
been investigated. Planning performance on the Tower of
London test was improved with modafinil [100]. All these
effects were investigated with single doses. Only a few studies
investigated the effects of repeated intakes [111], reporting
primarily subjective feelings of increased energy and wakeful-
ness. In the few studies in sleep-deprived individuals,
methylphenidate seemed primarily to improve subjective feel-
ings of energyandwakefulness, but had relatively small effects
on cognitive performance. However, modafinil improved
working memory, planning, decision making and flexibility
in sleep-deprived doctors [114] without showing the typical
side effects of caffeine, such as tremor and anxiety [115]. In
the case of atomoxetine, research into cognitive effects is still
ongoing. The most consistent finding is an improvement in
response inhibition [116,117].
(b) Non-pharmacological cognitive enhancement in
healthy people
Non-pharmacological methods, such as tDCS and TMS, have
been investigated regarding their cognition modulating and
enhancing functions. These methods apply magnetic fields
(TMS) or electrical currents (tDCS) to influence either the
activity and/or excitability of certain brain areas. Specifically,
tDCS is thought to have rather lasting, neuroplastic effects
[118]. One recent review [119] summarized studies applying
TMS in patients with neuropsychiatric disorders, such as
depression. Verbal learning improved in two studies
[120,121], as did executive function [122,123]. However, 8 of
13 studies found no effect on cognition. One of five studies
found positive effects on verbal learning in patients with
schizophrenia [124], and in patients with Alzheimer’s disease,
there were two positive studies. However, the few studies that
exist are unfortunately underpowered and only some are
sham-controlled. Therefore, this field requires more rigorous
research on stimulation location, dosage and target symp-
toms. While the evidence of an antidepressant effect of TMS
is established (Hedge’s g ¼ 0.55 in a meta-analysis [125])
and indeed approved for treatment-resistant depression by
the Food and Drug Administration, the evidence for clinical
therapeutic effects in other neuropsychiatric disorders and
also the effects on specific cognitive functions are still not
very strong, requiring more research. The safety profile of
TMS is well characterized [126,127]. TDCS, however, has
until now been much less investigated in treatment studies
(e.g. meta-analyses in depression based on six to seven studies
[128,129], only three double-blind placebo-controlled studies
on tDCS in tinnitus [118]), and only a few studies have exam-
ined the effects of tDCS on cognition in neuropsychiatric
disorders (e.g. improved working memory and verbal fluency
in schizophrenia [130]). The number of studies on cognitive
effects in healthy volunteers is somewhat larger, and they
point to improvements in a range of cognitive functions,
including memory and attention [131,132]. For instance, a
recent study compared the effect of prefrontal tDCS in
sleep-deprived healthy volunteers with those of caffeine and
found similar to even stronger improvements of vigilance/
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tDCS requires further research on safety and long-term effects
[134,135], particularly when considering the uncontrolled pur-
chasing over the internet and uncontrolled use of these
devices [136].
3. Summary and conclusion
In summary, these studies suggest that cognitive enhancers
such as smart drugs and devices have the potential to pro-
vide benefits in healthy people, although the extent and
specificity (which intervention affects which function and is
best applied in which situation) are still under investigation.
Other questions such as the safety of regular use in healthy
people and, even more importantly, the potential effects on
still-developing brains when used in healthy children and
adolescents require more research [5,135,137].
In addition to safety issues, there are also ethical concerns.
The exact numbers of healthy users of prescription drugs
with the intention to enhance cognition are unknown, with
estimates in the general population of less than 5%, although
in some studies in students, between 10% and 20% of the stu-
dents reported to have used prescription drugs within the
past year, without strong differences between the US and
Europe [110,138–142]. One study in a small competitive col-
lege reported use within the last year in more than 30% of the
students [143]. However, the prescription rates of stimulants
in England have been rising steadily from 220 000 in 1998 to
418 300 in 2004. The global market share of modafinil,
licensed in the UK for narcolepsy and excessive fatigue and
sleepiness in certain chronic medical conditions, was more
than $700 million per year [144], with an estimated ‘off-
label’ use of around 90% [145]. In the lay press, modafinil
has also gained a lot of attention as a pill that can boost
brain power, which reflects the interest of the public in
pharmacological enhancement of cognitive abilities such as
planning and problem solving. These numbers raise the ques-
tion as to why healthy people are using cognitive enhancing
drugs. Some studies in college students in the USA have
asked this question, and most students gave ‘improving intel-
lectual performance’, ‘being more efficient on academic
assignments’, ‘improving concentration’ and ‘being able to
study longer’ as motives, with only a few reporting rec-
reational ones [110]. This matches a report of the Academy
of Medical Sciences that a small percentage increment in per-
formance can lead to significant improvements in functional
outcome; it is conceivable that a 10% improvement in
memory score could lead to an improvement in an A-level
grade or degree class [146]. Therefore, many students are
using cognitive enhancing drugs to ‘get the competitive
edge’ over other students in exam situations. It might have
been this consideration that made Duke University prohibit
the use of prescription drugs by students without an author-
ized prescription. Duke University’s website specifies the
‘unauthorized use of prescription medication to enhance aca-
demic performance’ as cheating in the category ‘academic
dishonesty’ of their academic conduct policy [147].
Furthermore, particularly modafinil seems to affect motiv-
ation in a manner that makes unappealing tasks more
appealing and therefore they can be undertaken and com-
pleted more easily. In other words, overall task-related
pleasure is increased by modafinil [113]. This increase in
motivation is task-specific, and not a general stimulatingeffect [113]. A third reason reported is reducing the
effects of jet-lag and staying awake and alert for longer
periods of time.4. Further considerations
As responsible scientists and clinicians in the field of neuro-
science and mental health, we need to consider how our
discoveries and inventions will affect society [148–150]. In the
case of pharmacological cognitive enhancement, there are
many people with neuropsychiatric disorders who could
benefit greatly from these drugs. In the development of the
field of novel pharmacological cognitive enhancers, we must
gain maximum benefits with minimum harm to the individual
and to society as a whole. However, ethical considerations of
cognitive enhancement in healthy people are more complex,
ranging from potential benefits in surgeons, shift workers, mili-
tary, air traffic controllers and other fields where constant high
performance is essential, to fears of coercion [151] and competi-
tive pressure by peers, as well as increasing inequality with
access depending on wealth and also cheating (see above, aca-
demic dishonesty). These ‘smart drugs’ may alter the future of
work as we know it, particularly where shift work, jet lag and
high-risk decisions may compromise performance [152]. On the
other hand, as detailed above, scientific knowledge about the
specific effects and side effects in the healthy population, par-
ticularly with long-term use, is still limited. Therefore, we
need collaboration between scientists, pharmaceutical compa-
nies and governmental regulators to develop improved
substances, get them trialled, tested and licensed. With this
knowledge, neuroscientists together with social scientists, philo-
sophers, ethicists and society should actively discuss the ethical
and moral consequences of cognitive enhancement.
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